Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | PPARG | P37231 | 3/20 | 0.47 |
| ▸ | PPARA | Q07869 | 3/20 | 0.47 |
| ▸ | AGXT | P21549 | 2/20 | 0.44 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.43 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL276584 | 0.83 | CYP1A2 (0.58) | CYP2A6CYP1A2PPARGPPARAAGXT | |
| SCHEMBL9770329 | 0.79 | CYP2A6 (0.54) | CYP2A6CYP1A2PPARGPPARAAGXT | |
| SCHEMBL16893876 | 0.79 | PPARG (0.49) | CYP2A6CYP1A2PPARGPPARAAGXT | |
| SCHEMBL19655046 | 0.79 | CYP2A6 (0.54) | CYP2A6CYP1A2PPARGPPARAAGXT | |
| SCHEMBL7857138 | 0.79 | CYP1A2 (0.54) | CYP2A6CYP1A2PPARGPPARAAGXT | |
| SCHEMBL27612947 | 0.79 | CYP2A6 (0.54) | CYP2A6CYP1A2PPARGPPARAAGXT | |
| SCHEMBL11746367 | 0.79 | CYP1A2 (0.54) | CYP2A6CYP1A2PPARGPPARAAGXT | |
| SCHEMBL5701249 | 0.79 | CYP2A6 (0.59) | CYP2A6CYP1A2PPARGPPARAAGXT | |
| SCHEMBL9064518 | 0.79 | CYP1A2 (0.48) | CYP2A6CYP1A2PPARGPPARAAGXT | |
| SCHEMBL9064396 | 0.79 | PPARG (0.51) | CYP2A6CYP1A2PPARGPPARAAGXT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121621-B1 | LXR AND FXR MODULATORS | EXELIXIS PATENT CO LLC (US) | 2014-05-07 | — | — | EP | disclosed |
| CN-101434749-B | Polycarbonate resin composition | TEIJIN CHEMICALS LTD | 2012-06-20 | — | — | CN | disclosed |
| CN-101679297-B | LXR and FXR modulators | EXELIXIS INC | 2012-01-11 | — | — | CN | disclosed |
| US-7998995-B2 | LXR and FXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2011-08-16 | — | — | US | disclosed |
| CN-101679297-A | lxr and fxr modulators | EXELIXIS INC | 2010-03-24 | — | — | CN | disclosed |
| US-20100069367-A1 | LXR and FXR Modulators | EXELIXIS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| EP-2121621-A1 | LXR AND FXR MODULATORS | Exelixis, Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| CN-101434749-A | Polycarbonate resin composition | TEIJIN CHEMICALS LTD (JP) | 2009-05-20 | — | — | CN | disclosed |
| WO-2008073825-A1 | LXR AND FXR MODULATORS | EXELIXIS, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
| US-20050171185-A1 | Indole derivatives | FUJISAWA PHARMACEUTICAL CO., LTD., A JAPANESE CORPORATION | 2005-08-04 | — | — | US | disclosed |
| CN-1135224-C | Benzimidazole derivatives | ����ҩƷ��ҵ��ʽ���� | 2004-01-21 | — | — | CN | disclosed |
| US-6420409-B1 | GLUCOSE TOLERANCE, DIABETES,INSULIN RESISTANCE, POLYCYSTIC OVARY SYNDROME, HYPERLIPIDEMIA, ATHEROSCLEROSIS, CARDIOVASCULAR DISORDERS, HYPERGLYCEMIA, HYPERTENSION, STENOCARDIA, PULMONARY HYPERTENSION, CONGESTIVE HEART FAILURE, | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-07-16 | — | — | US | disclosed |
| US-6399658-B1 | REDUCING DRUG SIDE EFFECT | SUMITOMO PHARMACEUTICALS CO., LTD. (JP) | 2002-06-04 | — | — | US | disclosed |
| EP-1142880-A1 | BENZIMIDAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-10-10 | — | — | EP | disclosed |
| CN-1303371-A | Indole derivatives | FUJISAWA PHARMACEUTICAL CO (JP) | 2001-07-11 | — | — | CN | disclosed |
| EP-1070705-A1 | INDOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-01-24 | — | — | EP | disclosed |
| CN-1268123-A | Benzimidazole derivatives | FUJISAWA PHARMACEUTICAL CO (JP) | 2000-09-27 | — | — | CN | disclosed |
| EP-1020452-A1 | BENZIMIDAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-07-19 | — | — | EP | disclosed |
| EP-1004304-A1 | COMPOSITION CONTAINING ASCORBIC ACID | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2000-05-31 | — | — | EP | disclosed |
| EP-0733364-A1 | MEDICINAL COMPOSITION FOR CIRCULATORY ORGAN | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1996-09-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069367-A1 | LXR and FXR Modulators | NR1H3, NR1H2, NR1H4 | CYP2A6 116/4885CYP1A2 251/4885PPARG 40/4885 |
| US-20050171185-A1 | Indole derivatives | PDE5A, IGFBP5, HTR5A | CYP2A6 1223/4885CYP1A2 1222/4885PPARG 2279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.